Fuchs Endothelial Corneal Dystrophy clinical trials

Explore recruiting fuchs endothelial corneal dystrophy clinical trials.

Recruiting fuchs endothelial corneal dystrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fuchs Endothelial Corneal Dystrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy

Denmark, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy

Germany, Denmark, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehicle in Subjects with Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Fuchs Endothelial Corneal Dystrophy trials by city

Fuchs Endothelial Corneal Dystrophy in Toronto Fuchs Endothelial Corneal Dystrophy in Vancouver Fuchs Endothelial Corneal Dystrophy in Montreal Fuchs Endothelial Corneal Dystrophy in Calgary Fuchs Endothelial Corneal Dystrophy in Edmonton Fuchs Endothelial Corneal Dystrophy in Ottawa Fuchs Endothelial Corneal Dystrophy in Winnipeg Fuchs Endothelial Corneal Dystrophy in Quebec City Fuchs Endothelial Corneal Dystrophy in Hamilton Fuchs Endothelial Corneal Dystrophy in Kitchener Fuchs Endothelial Corneal Dystrophy in London Fuchs Endothelial Corneal Dystrophy in Halifax Fuchs Endothelial Corneal Dystrophy in New York Fuchs Endothelial Corneal Dystrophy in Los Angeles Fuchs Endothelial Corneal Dystrophy in Chicago Fuchs Endothelial Corneal Dystrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease